JP2017516868A - 持続性抑制を増加させ、二次性不眠症を治療する方法 - Google Patents

持続性抑制を増加させ、二次性不眠症を治療する方法 Download PDF

Info

Publication number
JP2017516868A
JP2017516868A JP2017516256A JP2017516256A JP2017516868A JP 2017516868 A JP2017516868 A JP 2017516868A JP 2017516256 A JP2017516256 A JP 2017516256A JP 2017516256 A JP2017516256 A JP 2017516256A JP 2017516868 A JP2017516868 A JP 2017516868A
Authority
JP
Japan
Prior art keywords
sleep
patient
disease
thip
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017516256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516868A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2017516868A publication Critical patent/JP2017516868A/ja
Publication of JP2017516868A5 publication Critical patent/JP2017516868A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
JP2017516256A 2014-06-06 2015-06-03 持続性抑制を増加させ、二次性不眠症を治療する方法 Withdrawn JP2017516868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
US62/008,939 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019217208A Division JP2020063264A (ja) 2014-06-06 2019-11-29 持続性抑制を増加させ、二次性不眠症を治療する方法

Publications (2)

Publication Number Publication Date
JP2017516868A true JP2017516868A (ja) 2017-06-22
JP2017516868A5 JP2017516868A5 (enExample) 2018-05-17

Family

ID=54767324

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017516256A Withdrawn JP2017516868A (ja) 2014-06-06 2015-06-03 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2019217208A Withdrawn JP2020063264A (ja) 2014-06-06 2019-11-29 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2021116935A Withdrawn JP2021178836A (ja) 2014-06-06 2021-07-15 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2023088456A Pending JP2023123442A (ja) 2014-06-06 2023-05-30 持続性抑制を増加させ、二次性不眠症を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019217208A Withdrawn JP2020063264A (ja) 2014-06-06 2019-11-29 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2021116935A Withdrawn JP2021178836A (ja) 2014-06-06 2021-07-15 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2023088456A Pending JP2023123442A (ja) 2014-06-06 2023-05-30 持続性抑制を増加させ、二次性不眠症を治療する方法

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3372229B1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124366T1 (enExample)
DK (2) DK3151832T3 (enExample)
ES (2) ES2876350T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX380868B (enExample)
PL (2) PL3372229T3 (enExample)
PT (2) PT3372229T (enExample)
RS (2) RS62006B1 (enExample)
SI (2) SI3372229T1 (enExample)
SM (2) SMT202100340T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020063264A (ja) * 2014-06-06 2020-04-23 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2022093199A (ja) * 2020-12-11 2022-06-23 東洋インキＳｃホールディングス株式会社 貼付剤
JP2022540917A (ja) * 2019-07-15 2022-09-20 オービッド・セラピューティクス・インコーポレイテッド 治療的処置のためのガボキサドール含有医薬製剤

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20240285562A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501301A (ja) * 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
MX391708B (es) * 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501301A (ja) * 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEVELOPMENTAL NEUROSCIENCE, vol. 33, JPN6018051692, 2011, pages 395 - 403, ISSN: 0004231859 *
EGAWA,K: "DECREASED TONIC INHIBITION IN CEREBELLAR GRANULE CELLS CAUSES MOTOR DYSFUNCTION IN A 以下備考", SCIENCE TRANSLATIONAL MEDICINE, vol. VOL. 4, ISSUE 163, JPN5017004690, 2012, pages 1 - 10, ISSN: 0004231860 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020063264A (ja) * 2014-06-06 2020-04-23 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2022540917A (ja) * 2019-07-15 2022-09-20 オービッド・セラピューティクス・インコーポレイテッド 治療的処置のためのガボキサドール含有医薬製剤
JP2022093199A (ja) * 2020-12-11 2022-06-23 東洋インキＳｃホールディングス株式会社 貼付剤
JP7600661B2 (ja) 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Also Published As

Publication number Publication date
ES2876350T3 (es) 2021-11-12
AU2020217342A1 (en) 2020-08-27
US20230051859A1 (en) 2023-02-16
US9339495B2 (en) 2016-05-17
HRP20210901T1 (hr) 2021-09-17
IL268960A (en) 2019-10-31
HRP20210902T1 (hr) 2021-09-17
AU2024202604A1 (en) 2024-05-09
US20180015076A1 (en) 2018-01-18
US20160228418A1 (en) 2016-08-11
US9801864B2 (en) 2017-10-31
AU2020217342B2 (en) 2021-10-07
US20150352085A1 (en) 2015-12-10
IL249287B (en) 2021-03-25
CY1124366T1 (el) 2022-07-22
JP2021178836A (ja) 2021-11-18
US20170273956A1 (en) 2017-09-28
US20160038469A1 (en) 2016-02-11
AR100772A1 (es) 2016-11-02
MX2016016136A (es) 2017-07-05
CA2950845A1 (en) 2015-12-10
SMT202100340T1 (it) 2021-07-12
CY1124368T1 (el) 2022-07-22
CA2950845C (en) 2023-04-25
SI3372229T1 (sl) 2021-09-30
AU2015269667A1 (en) 2016-12-22
US11278529B2 (en) 2022-03-22
PL3151832T3 (pl) 2021-10-25
US9744159B2 (en) 2017-08-29
LT3372229T (lt) 2021-07-12
DK3372229T3 (da) 2021-06-14
DK3151832T3 (da) 2021-06-14
US20220016091A1 (en) 2022-01-20
EP3151832A1 (en) 2017-04-12
US20250025448A1 (en) 2025-01-23
JP2023123442A (ja) 2023-09-05
AU2015269667B2 (en) 2020-07-30
US20180303805A1 (en) 2018-10-25
AU2022200085A1 (en) 2022-02-03
US20170071917A1 (en) 2017-03-16
HUE055400T2 (hu) 2021-11-29
PL3372229T3 (pl) 2021-10-04
MX380868B (es) 2025-03-12
RS62007B1 (sr) 2021-07-30
EP3372229A1 (en) 2018-09-12
JP2020063264A (ja) 2020-04-23
US20170087133A1 (en) 2017-03-30
EP3795156A1 (en) 2021-03-24
RS62006B1 (sr) 2021-07-30
LT3151832T (lt) 2021-07-12
IL249287A0 (en) 2017-02-28
HUE055155T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
IL268960B (en) 2021-05-31
EP3151832B1 (en) 2021-03-24
SMT202100343T1 (it) 2021-07-12
MX391502B (es) 2025-03-21
PT3372229T (pt) 2021-06-17
EP3372229B1 (en) 2021-03-24
ES2875742T3 (es) 2021-11-11
WO2015187851A1 (en) 2015-12-10
US9446028B2 (en) 2016-09-20
PT3151832T (pt) 2021-06-15
MX2020012404A (es) 2022-04-11
SI3151832T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
US20250025448A1 (en) Methods of increasing tonic inhibition and treating secondary insomnia
CN105744932B (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
WO2015171547A1 (en) Methods of treating cognitive impairment associated with neurodegenerative disorders
JP2021502403A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
JP2022540253A (ja) Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
EP4007581A1 (en) Dosing protocols and regimens for aminosterol treatment
WO2015153971A1 (en) Methods of treating sleep disorders associated with neurodegenerative diseases
HK1260775A1 (en) Methods of increasing tonic inhibition and treating angelman syndrome
EP4551223A1 (en) Oral liposomal formulations of fasudil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191129

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200204

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200212

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200317

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200923

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210511

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210615

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210615

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210721